INAB Stock Analysis: Buy, Sell, or Hold?
INAB - IN8bio, Inc. Common Stock
$1.39
-0.06 (-4.22%)
▼
5d:
-9.82%
30d:
-14.54%
90d:
-30.21%
HOLD
LOW Confidence
Analysis Updated: Jun 10, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When INAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INAB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INAB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INAB is currently trading at $1.39, which is considered oversold relative to its 30-day fair value range of $1.47 to $1.71.
Technical Outlook: Technically, INAB is in a downtrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.25 (+331.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INAB is in a downtrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.25 (+331.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.47 -
$1.71
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- BULLISH: Trading 331.0% below Wall St target ($6.25)
- CAUTION: Recommendation downgraded due to -9.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.47 -
$1.71
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.40
Resistance Level
$1.88
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.37
Wall Street Target
$6.25
(+331.0%)
Share & Embed Analysis
Last updated: June 10, 2026 1:55 PM ET
Data refreshes hourly during market hours. Next update: 2:55 PM
Data refreshes hourly during market hours. Next update: 2:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 53 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 54 HOLD |
